These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 18318249)
41. Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia. Mandell LA; Jones RN Diagn Microbiol Infect Dis; 2002 Sep; 44(1):127-8. PubMed ID: 12376042 [No Abstract] [Full Text] [Related]
42. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. Milkovich G Pharmacotherapy; 2001 Jul; 21(7 Pt 2):83S-88S. PubMed ID: 11446523 [TBL] [Abstract][Full Text] [Related]
43. Endocarditis diagnosed as multilobar, community acquired pneumonia. Muntan CD; Haydel M Emerg Med J; 2004 Mar; 21(2):244-5. PubMed ID: 14988364 [No Abstract] [Full Text] [Related]
44. 52-year-old man with shortness of breath. Aviles RJ; Dockrell DH; Thompson RL Mayo Clin Proc; 2000 Apr; 75(4):417-20. PubMed ID: 10761500 [No Abstract] [Full Text] [Related]
45. Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection. Matsuo K; Azuma M; Kasai M; Hanji I; Kimura I; Kosugi T; Suga N; Satoh M J Pharm Pharm Sci; 2009 Jan; 11(2):111s-117s. PubMed ID: 19203473 [TBL] [Abstract][Full Text] [Related]
46. [Community-acquired pneumonia in the fragile elderly]. Marti J; Novo I Rev Esp Geriatr Gerontol; 2008; 43(6):388-9. PubMed ID: 19080957 [No Abstract] [Full Text] [Related]
47. [Community acquired pneumonia by Corynebacterium spp. in a immunocompetent patient]. Chico C; Batalla B; Javaloyas M; RodrÃguez E An Med Interna; 2007 Feb; 24(2):100-1. PubMed ID: 17595737 [No Abstract] [Full Text] [Related]
48. Community acquired pneumonia. CME Infectious diseases--II. Jolobe OM J R Coll Physicians Lond; 1998; 32(5):491-2. PubMed ID: 9819750 [No Abstract] [Full Text] [Related]
50. [Myeloradiculoneuritis of Mycoplasma pneumoniae: a case report]. Loussaief C; Battikh R; Louzir B; M'saddek F; Abdelhafidh NB; Bahri M; Mâalaoui H; Ajmi F; Othmani S Rev Med Interne; 2003 Apr; 24(4):273-5. PubMed ID: 12706790 [No Abstract] [Full Text] [Related]
51. Anaphylactic reaction to ciprofloxacin in a toddler: successful desensitization. Erdem G; Staat MA; Connelly BL; Assa'ad A Pediatr Infect Dis J; 1999 Jun; 18(6):563-4. PubMed ID: 10391195 [No Abstract] [Full Text] [Related]
52. Use of oral ciprofloxacin in community-acquired pneumonia. Chrysanthopoulos CJ; Bassaris HP J Chemother; 1989 Apr; 1(2):103-6. PubMed ID: 2732778 [TBL] [Abstract][Full Text] [Related]
53. Multidisciplinary approach to improving treatment of community-acquired pneumonia. Cregin R; Segal-Maurer S; Weinbaum F; Rahal J; Kabrowitz S; Sixsmith D; Cassata V; Danek M; Battleman D; Callahan M Am J Health Syst Pharm; 2002 Feb; 59(4):364-8. PubMed ID: 11885401 [No Abstract] [Full Text] [Related]
54. The treatment of primary atypical pneumonia with intravenous doxycycline: a report of clinical observations. Coll J; Cabrer B; Cano JF; Vivancos J; Balcells A Infection; 1976; 4(1 Suppl):53-4. PubMed ID: 955702 [TBL] [Abstract][Full Text] [Related]
55. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination. Somasundaram C; Nicklas W; Matzku S In Vitro Cell Dev Biol; 1992; 28A(11-12):708-10. PubMed ID: 1483961 [No Abstract] [Full Text] [Related]
59. The use of ciprofloxacin for the elimination of mycoplasma from naturally infected cell lines. Mowles JM Cytotechnology; 1988 Nov; 1(4):355-8. PubMed ID: 22359171 [TBL] [Abstract][Full Text] [Related]
60. [Clinical effects of intravenous ciprofloxacin on community-acquired pneumonia with positive Immunocard Mycoplasma test results]. Okimoto N; Nanba F; Kibayashi T; Kishimoto M; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N Nihon Kokyuki Gakkai Zasshi; 2008 Feb; 46(2):92-5. PubMed ID: 18318249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]